Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastic Drugs
- Alkylating Antineoplastics
- Antineoplastic Alkylating Agents
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Agents, Antineoplastic
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 03 01; 27(5):1278-1286.
-
Persistent HCMV infection of a glioblastoma cell line contributes to the development of resistance to temozolomide. Virus Res. 2020 01 15; 276:197829.
-
Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. World Neurosurg. 2019 Jul; 127:31-37.
-
Nanosized complexation assemblies housed inside reverse micelles churn out monocytic delivery cores for bendamustine hydrochloride. Eur J Pharm Biopharm. 2017 Apr; 113:198-210.
-
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncol. 2017 01; 6(1):29-43.
-
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016 Apr; 124(4):998-1007.
-
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
-
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014 Nov; 21(12):3931-7.
-
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. J Med Chem. 2013 Sep 12; 56(17):6845-57.
-
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. J Popul Ther Clin Pharmacol. 2013; 20(2):e132-45.